Start main content

Anti-DKK1 Monoclonal Antibody for Liver Cancer Treatment

Anti-DKK1 Monoclonal Antibody for Liver Cancer Treatment
Therapeutic Biologics
Reference No.

Key Problem and Market Opportunity

  • Liver cancer (Hepatocellular carcinoma, HCC) is the second leading cause of cancer death in men and ninth in women. There were over 780,000 new cases worldwide with 50% of total accounted in China. (American Cancer Society, 2015)
  • At present, there are only a few molecular targeted therapies for HCC patients, and anti-DKK1 antibody has not been considered for treating HCC, which may be a potential therapy and additional option for HCC patients.
  • Data showed that DKK1 enhanced growth of HCC cells in vivo.

Key Advantages of the Technology

Technology Section Slider 1
Technology Section Slider 2
  • In vitro test on HCC cell lines showed that anti-DKK1 antibody is able to suppress cell migration of HCC cells.
  • In vivo test on mice demonstrated the suppressive effect of anti-DKK1 monoclonal antibody on the growth of HCC tumor.
  • Data shows that serum levels of DKK1 could serve as a prognosis of HCC for patients.
  • Figure 1: Anti-DKK1 antibody was able to inhibit the migration of cell when compared to the control group.
  • Figure 2: Tumor size and mass in mice decreased when injected with DKK1 antibody, indicating that anti-DKK1 antibody is able to suppress tumor growth.

Potential Product and Services

  • Anti-DKK1 antibody as treatment for HCC patients
  • Anti-DKK1 antibody against cancer metastasis in HCC patients

Development Status

  • US Patent Application No. 13/361,439;
  • Chinese Patent No. ZL201280016543.1 issued on 13 Apr 2016;
  • EP Patent No. 2670435 issued on 23 Aug 2017
IP Status
  • Patented
  • Patent application submitted

Work with us